Vancouver, BC, Las Vegas, NV – November 2nd, 2023  (CSE: OVAT and OTC: OVATF) – Ovation Science USA Inc. (“Ovation” or the “Company”), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the signing of an exclusive licensing agreement for Ovation’s topical / transdermal formulations for the state of Missouri. The Company’s new licensee is MidWest Roots, LLC (“MidWest”); a company with a 65,000 square foot cannabis processing facility; one of the largest in Missouri.

Under the terms of the Agreement, MidWest will be responsible for all regulatory, manufacturing, marketing, sales and distribution activities for Ovation’s formulations in the state of Missouri. Ovation will receive royalty income based on wholesale sales to dispensaries. Missouri is approved for adult-use and is growing rapidly, with over 200 dispensaries and already achieving $1.3 billion in sales this year as of the end of August 2023, and according to Headset.io, the sixth largest market. MidWest, known for its expertise in cannabis and consumer goods, is poised to enter the market with Ovation’s products in late Q4 of 2023.

“We are excited to partner with MidWest to bring our innovative topical cannabis products to the Missouri market, said Terry Howlett, President of Ovation. “MidWest has not only a strong production division but also a dynamic team that understands the market including Ovation’s topicals. They have a strong track record of success in the cannabis and consumer goods industry, and we believe that they are the perfect partner to generate revenue in Missouri and bring value for our shareholders.””We are thrilled to bring Ovation’s products to consumers in Missouri. Their products are some of the most effective topical cannabis products on the market, and we believe that they will be a valuable addition to our product line”, said Chris Klein, CEO of Midwest Roots, LLC. “We look forward to launching these products and working with the Ovation team to make it a great success.”

This is the fourth agreement announced by Ovation this year. It follows a recently announced license agreement with Planet 13 for Nevada, a license for Pennsylvania with PA Options for Wellness and a Supply and Distribution Agreement with Golfer’s CBD Ltd. Ovation leverages its expertise in the pharmaceutical industry by using its patented skin delivery technology Invisicare® in its highly effective, proprietary products. Invisicare, backed by over 20 years of research and development, enables substantially more CBD and THC and other cannabinoids to be delivered to and through the skin, which translates into better results for patients. In a recent in-house study, Ovation compared five CBD brand leaders to Ovation Science’s topical CBD cream. All competitor creams tested release less than 2% CBD compared to 40% release from Ovation Science over two hours.

About MidWest Roots, LLC

Midwest Roots has a 65,000 square foot facility for the production of wide variety of cannabis products to serve the Missouri recreational and medical cannabis patients. It is one of the largest facilities in Missouri. Its facility is located in Washington, MO, near Interstates 44 and 70 which makes it an ideal location allowing the company to get the products to dispensaries across the state in a matter of business days. The company produces a variety of cannabis products, including topicals, vape pens, cannabis-infused edibles, pills and (coming soon) pre-rolled joints.

About Ovation Science Inc.

Ovation Science USA Inc, a wholly-owned subsidiary of Ovation Science Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“wellness” line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation’s management and science team have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.

Stock symbols: CSE under the symbol OVAT and OVATF in the USA on OTC Markets.

Websites: CORPORATE: ovationscience.com

WELLNESS: invibemd.com, BEAUTY: arlocbdbeauty.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state cited, continued sales in dispensaries or in retail markets or expansion to other states. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CORPORATE INQUIRIES:

Doreen McMorran: info@ovationscience.com

PH: PH: 604-982-5700

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

If a company has developed very effective, transformative technology, it takes an investment into research and development and time.  It also pays to protect it from copycats and pirates with patents. And if the company’s specialty is science and product development rather than in retail sales and marketing, a royalty- or license-based revenue model could make more sense than investing and building the infrastructure for a multi-market sales organization.

These three characteristics – completed research and development, intellectual property, and recurring royalty revenue – are the hallmarks of the business model for Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF). Investors may be attracted to the company for the protection provided by the patents, the multiple market opportunities, and the simplicity of the revenue model. Ovation’s central innovation is the Invisicare® skin delivery platform, a polymer technology that greatly enhances the durability, effectiveness, and deliverability of cannabinoids (like CBD and THC) on and through the skin.

Patents

Ovation’s products are all delivered by its Invisicare technology.  This underlying technology is patented in eleven countries, including the US, Canada, four European countries, China, and India. Ovation’s products are protected by various patents or patents-pending; depending on the product The company has further patent protection on individual products like its CBD sunscreen As well Ovation has also applied for patents in the US and Canada to cover its transdermal applications of its CBD: THC combo products. Transdermal treatments are intended to deliver active ingredients like CBD and THC through the skin and work systemically throughout the body.

For both Ovation’s topical or transdermal creams, Invisicare® polymers greatly enhance the duration and amount of active ingredients delivered. For topicals, the company found its technology released 40% of active ingredients compared to 3% for market-leading formulations at 2 hours. For its transdermal creams, Invisicare® provided an 80% penetration rate after 4 hours compared to a range of 10% – 25% for market-leading products. This is exactly the type of technology that needs to be protected and can lead to attractive returns over the life of the patent (often 20 years).

Royalty Revenue Model

The investment of 20 years doing research and development of the novel Invisicare® polymers and over thirty CBD and/or THC formulations is already completed. With the technology in hand, the company is now in the phase of commercialization through royalty and licensing agreements. For most arrangements, an established and licensed operator in a given market will license the rights to Ovation’s formulations and purchase the Invisicare polymers from the company and manufacture the proven Ovation-formulated products with them. That licensee is the exclusive representative of Ovation’s products in that market, be it a state or province or country. Once sold, Ovation receives a  percentage of the wholesale revenue generated, usually a double-digit royalty.

The model reduces the risk to Ovation and its investors. The R&D phase is complete, the product works, the patents are secured. At this point, the catalysts for the company are basically revenue growth with existing licensees and the addition of new partnerships to broaden the market.

In an international industry as explosive and young as the legal cannabis and hemp sectors, Ovation’s position is rare and filled with potential. The company’s main market right now is expansion across the USA, but there are obviously more fish to fry internationally as well. Keep an eye for further developments in the coming quarters as Ovation executes its expansion plans.

Click here to learn more about investing in patented skincare technology

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

As the legal cannabis industry matures and expands, the goal of many companies is (and should be) to reach people who might not historically be cannabis consumers. According to a 2020 Gallup poll, about 12% of US adults say they smoke marijuana. This percentage has remained fairly steady over the past several years, even in the face of widespread legalization. In order to reach a much wider market, the industry clearly needs options that don’t involve smoking.

Enter cannabis-derived products, such as tinctures, creams, and edibles. People who don’t like the idea of smoking may well be inclined to try some of these alternate products. Add in the recent boom in CBD products stemming from the delisting of hemp as a dangerous drug, and suddenly you have a much more robust marketplace than the one relying on cannabis smokers. When Martha Stewart is offering CBD products, you know something has changed.

What hasn’t changed? The need to distinguish your products from the masses. One way to do that is to employ technology that makes your products more effective than others, increasing the likelihood of satisfied and repeat customers. Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF) is a company that has done the heavy lifting when it comes to topical and transdermal products with its patented Invisicare® cannabinoid delivery system. Ovation has researched, formulated, and tested over 30 products to date, all of which feature the enhanced deliverability and effectiveness of its Invisicare® technology.

Ovation Works With Licensees, Multi-State Operators

Ovation Science runs its own online sales operations, with Invibe MD targeting the health and wellness sector and ARLO CBD Beauty targeting the beauty and skincare market. Beyond those sites, however, the bulk of the company’s business model consists of partnerships with established operators in the US and Canada. Rather than trying to set up shop in various states and provinces, Ovation offers its Invisicare® technology, and the resulting products, to companies that have already navigated the various regulatory environments across the continent.

Click here to learn more about investing in patented skincare technology

The arrangements can take different forms. With its Nevada licensee, for instance, Ovation provides the Invisicare® polymer technology, the product formulations, and the accompanying intellectual property protection. The licensee takes care of product manufacturing and distribution. Other licensees may do the same, or they may choose to employ Ovation’s R&D capabilities to create entirely new products utilizing Invisicare®. Either way, Ovation has the infrastructure, the expertise, and the history to get products into the market quickly for its partners.

Ovation’s technology is scalable to fit whatever the licensee’s requirements and capabilities may be. The company makes it as easy as possible for its partners to create new lines of widely-appealing cannabis-derived products, improve existing product lines, or simply market Ovation’s existing products under their own brand.

The key for Ovation’s exclusive partners is the performance of the product, and the protection of knowing nobody else can make those products in a particular market. The performance is really impressive. The company tested its topical (ingredients to be delivered ON the skin) formulations against a number of leading CBD topicals. The results were staggering, with Invisicare® products demonstrating a 40% active ingredient release rate over a two hour period compared to an average of 3% for the other creams tested. Results were similar for transdermal (ingredients to be delivered THROUGH the skin) formulas, with Invisicare® providing an 80% penetration rate after six hours compared to 10% to 25% for the other products.

Click here to learn more about investing in patented skincare technology

Ovation Science is Worth a Look

Whether you are a cannabis retailer looking for a competitive advantage in the booming cannabis-derived products space, or an investor looking for credible and compelling cannabis companies in the public markets, Ovation Science may be worth the time to investigate. The company brings 20 years of patent-protected scientific research and development to a product space that previously has been long on claims and short on proof. It’s a young industry with loads of upside for innovators such as Ovation Science.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.